<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24184" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lennox Gastaut Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Amrutkar</surname>
            <given-names>Chaitanya V.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Riel-Romero</surname>
            <given-names>Rosario M.</given-names>
          </name>
          <aff>Louisiana State University in Shreveport</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Chaitanya Amrutkar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rosario Riel-Romero declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24184.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Lennox-Gastaut syndrome (LGS) is a rare but severe form of childhood epilepsy. LGS is characterized by a triad of multiple seizure types, characteristic electroencephalogram (EEG) findings, and intellectual impairment. This activity reviews the cause, pathophysiology and presentation of LGS and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the etiology of Lennox-Gastaut syndrome.</p></list-item><list-item><p>Describe the presentation of Lennox-Gastaut syndrome.</p></list-item><list-item><p>Summarize the treatment of Lennox-Gastaut syndrome.</p></list-item><list-item><p>Review the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by Lennox-Gastaut syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24184&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24184">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24184.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Lennox-Gastaut syndrome (LGS) is a rare but severe form of childhood epilepsy that was first described by Dr. Henri Gastaut in Marseille, France in 1966.<xref ref-type="bibr" rid="article-24184.r1">[1]</xref>. Dr. William G. Lennox from Boston, United States, described the characteristic electroencephalogram (EEG) features of this condition.<xref ref-type="bibr" rid="article-24184.r2">[2]</xref>&#x000a0;The syndrome is aptly named after these two neurologists. LGS is characterized by a triad of multiple seizure types, characteristic EEG findings,<xref ref-type="bibr" rid="article-24184.r3">[3]</xref>&#x000a0;and intellectual impairment.<xref ref-type="bibr" rid="article-24184.r4">[4]</xref><xref ref-type="bibr" rid="article-24184.r5">[5]</xref>&#x000a0;It is one of the epileptic encephalopathies.<xref ref-type="bibr" rid="article-24184.r6">[6]</xref></p>
      </sec>
      <sec id="article-24184.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Lennox-Gastaut syndrome (LGS) can occur for&#x000a0;many reasons; however, approximately 25% of cases have no identified cause. Etiology can be divided into two subtypes:</p>
        <list list-type="order">
          <list-item>
            <p><bold>Secondary or Symptomatic LGS:</bold> An underlying pathology can be identified with this subtype and is usually from diffuse cerebral injury. Secondary LGS constitutes approximately 75% of cases.<xref ref-type="bibr" rid="article-24184.r7">[7]</xref>&#x000a0;Causes include tuberous sclerosis, infections/inflammation such as encephalitis, meningitis, injuries to the frontal lobes of the brain, birth injury/trauma, metabolic causes, and developmental brain malformations. West syndrome, or infantile spasms, is not a specific cause of LGS, but about 30% of children who develop LGS have a prior history of West syndrome<xref ref-type="bibr" rid="article-24184.r8">[8]</xref> and usually have a more severe clinical course.<xref ref-type="bibr" rid="article-24184.r9">[9]</xref>. Secondary LGS tends to have a worse prognosis.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Idiopathic or Cryptogenic LGS:&#x000a0;</bold>No underlying pathology can be identified in this subtype, and LGS tends to have a later onset<xref ref-type="bibr" rid="article-24184.r9">[9]</xref>; however, recent genetic studies have found de novo mutations in certain genes, including SCN1A,<xref ref-type="bibr" rid="article-24184.r10">[10]</xref>&#x000a0;GABRB3, ALG13, and CHD2.<xref ref-type="bibr" rid="article-24184.r11">[11]</xref><xref ref-type="bibr" rid="article-24184.r12">[12]</xref><xref ref-type="bibr" rid="article-24184.r13">[13]</xref>&#x000a0;The significance and actual contribution of these mutations to the development of LGS is unknown&#x000a0;at this time.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24184.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Lennox-Gastaut syndrome (LGS) accounts for approximately 2-5% of all childhood epilepsies,<xref ref-type="bibr" rid="article-24184.r14">[14]</xref><xref ref-type="bibr" rid="article-24184.r15">[15]</xref>&#x000a0;but it is responsible for roughly 10% of epilepsy cases occurring before the age of five years.<xref ref-type="bibr" rid="article-24184.r16">[16]</xref><xref ref-type="bibr" rid="article-24184.r7">[7]</xref><xref ref-type="bibr" rid="article-24184.r15">[15]</xref><xref ref-type="bibr" rid="article-24184.r17">[17]</xref><xref ref-type="bibr" rid="article-24184.r18">[18]</xref>&#x000a0;The incidence of LGS is estimated at 0.1 to 0.28 per 100,000 population.<xref ref-type="bibr" rid="article-24184.r7">[7]</xref>&#x000a0;In children, the incidence is estimated at 2 per 100,000.<xref ref-type="bibr" rid="article-24184.r7">[7]</xref>. The overall prevalence is about 26 per 100,000 people.<xref ref-type="bibr" rid="article-24184.r7">[7]</xref>&#x000a0;LGS is more common in males than in females<xref ref-type="bibr" rid="article-24184.r16">[16]</xref>. There are no reports about racial differences. As diffuse brain injury is responsible for a majority of cases, children with developmental and/or intellectual problems are more frequently diagnosed with LGS.</p>
      </sec>
      <sec id="article-24184.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>As mentioned, Lennox-Gastaut syndrome (LGS) is characterized by a triad of multiple seizure types, characteristic electroencephalogram (EEG) findings, and intellectual impairment.<xref ref-type="bibr" rid="article-24184.r5">[5]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Seizures</bold>: Seizures begin in early childhood, usually between the ages of 1 and 7 years, peaking at around 3 years.<xref ref-type="bibr" rid="article-24184.r14">[14]</xref>&#x000a0;Multiple seizure types are seen including tonic, atonic or drop attacks, atypical absence, myoclonic, and generalized tonic-clonic. Tonic seizures are most commonly seen, often occur at night, and are a distinctive feature of LGS.<xref ref-type="bibr" rid="article-24184.r19">[19]</xref>&#x000a0;Atypical absence seizures are the second most common subtype seen in LGS. They differ from typical absence seizures in that they have more than just staring episodes associated with eye blinking. Atonic seizures, also known as drop attacks,&#x000a0;are seen in over half of the patients and can cause recurrent falls and consequent injuries. Control of&#x000a0;atonic&#x000a0;seizures is considered an important factor in guiding treatment because of the risks associated with recurrent falls. Approximately half of the patients with LGS go into non-convulsive status epilepticus at some point. It can present with dizziness, staring, apathy, stupor, and unresponsiveness and adds to developmental delay and eventual cognitive issues.<xref ref-type="bibr" rid="article-24184.r5">[5]</xref>&#x000a0;It is difficult to identify seizure types in a majority of patients because of the multiple, daily seizure episodes.<xref ref-type="bibr" rid="article-24184.r5">[5]</xref><xref ref-type="bibr" rid="article-24184.r19">[19]</xref>&#x000a0;Another confounding factor in the identification of seizures is the emergence of different seizure types over time and a change in frequency. Continuous or video EEG monitoring can be helpful in identifying seizure types in this scenario.<xref ref-type="bibr" rid="article-24184.r20">[20]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Characteristic EEG pattern: </bold>Please&#x000a0;see the "Evaluation" section.</p>
          </list-item>
          <list-item>
            <p><bold>Intellectual Impairment:</bold>&#x000a0;The initial growth in a child with LGS is unremarkable. The decline is seen only after the seizures start and is in the form of developmental delay, intellectual impairment, diminished learning abilities, and behavioral problems. This decline is observed in the majority of the patients and gets worsens with age.<xref ref-type="bibr" rid="article-24184.r5">[5]</xref><xref ref-type="bibr" rid="article-24184.r19">[19]</xref><xref ref-type="bibr" rid="article-24184.r21">[21]</xref>&#x000a0;Memory and cognition can still be normal in up to 20% of patients, but these patients will lag in processing information. Patients with LGS show psychomotor regression which means a loss of previously acquired skills. Behavior problems include irritability, hyperactivity, and psychosis.<xref ref-type="bibr" rid="article-24184.r22">[22]</xref>&#x000a0;Sometimes, it is difficult to differentiate seizures from behavioral issues. Most patients will eventually have a cognitive disability and static encephalopathy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24184.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Lennox-Gastaut syndrome (LGS) is diagnosed based on appropriate clinical history (seizure types and intellectual impairment)&#x000a0;in the presence of characteristic electroencephalogram (EEG) criteria.<xref ref-type="bibr" rid="article-24184.r5">[5]</xref><xref ref-type="bibr" rid="article-24184.r19">[19]</xref>&#x000a0;A standard evaluation with comprehensive birth (prenatal, perinatal, postnatal) history, history of presenting illness/seizures since the onset, history of associated complaints like psychomotor regression, and a full systemic and neurological examination is necessary. Laboratory investigations include hematology and chemistry panel, urinalysis, urine drug screen, serum ammonia, lactic acid, serum amino acids, acylcarnitine profile, and urine organic acids. Imaging studies include magnetic resonance imaging (MRI) of the brain with and without contrast with seizure protocol. An EEG with awake and sleep recording (with activating procedures such as photic stimulation and hyperventilation if possible) is essential. A video EEG may be done to capture and characterize the different seizure types.</p>
        <p><bold>Characteristic EEG Pattern:&#x000a0;</bold>The background activity usually shows generalized slowing with bursts of spike and wave discharges (1.5 to 2.5 Hertz) and paroxysms of fast activity (10 to 20 Hertz).<xref ref-type="bibr" rid="article-24184.r5">[5]</xref><xref ref-type="bibr" rid="article-24184.r19">[19]</xref><xref ref-type="bibr" rid="article-24184.r23">[23]</xref>&#x000a0;The spike and wave activity has the highest amplitude over the frontal region, can be periodic or continuous, and can be focal or generalized. Sleep EEG is very important as there are some electrographic features that are activated during sleep and/or seen exclusively during sleep.<xref ref-type="bibr" rid="article-24184.r5">[5]</xref>&#x000a0;The spike and wave epileptiform discharges are more frequent and generalized during the non-rapid eye movement (non-REM) EEG as compared to the REM EEG. Tonic seizures are difficult to diagnose, especially in sleep. It is difficult to differentiate the EEG pattern of tonic seizures from infantile spasm.</p>
        <p>Diagnosis of idiopathic/cryptogenic LGS can be a challenge initially as the EEG might not be classic, seizures and clinical symptoms evolve&#x000a0;over time, and there is no biological marker for the disease. Regular follow up and repeat EEGs are needed to arrive at the final diagnosis.</p>
      </sec>
      <sec id="article-24184.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of&#x000a0;Lennox-Gastaut syndrome (LGS) revolves around seizure control and includes medical, dietary, and surgical management.&#x000a0;Seizure control is associated with improvement in cognition, mood, alertness, and overall quality of life.&#x000a0;</p>
        <p><bold>Medical Management:&#x000a0;</bold>The goal of treatment in LGS is seizure control. Medications help, but only to a certain extent. Seizures are usually refractory, are of different types, and need multiple medications. Control of tonic and atonic seizures&#x000a0;are&#x000a0;usually given priority because of associated falls and accidents.<xref ref-type="bibr" rid="article-24184.r24">[24]</xref><xref ref-type="bibr" rid="article-24184.r25">[25]</xref>&#x000a0;Complications arise frequently because when one medication controls one type of seizures, it can cause or worsen another already existent&#x000a0;seizure&#x000a0;type. For example, carbamazepine might worsen drop attacks. Thus, knowing seizure types becomes important. Multiple medications have been approved for LGS including felbamate, lamotrigine, rufinamide, valproate, benzodiazepines,&#x000a0;topiramate, and recently, cannabidiol oral solution.<xref ref-type="bibr" rid="article-24184.r26">[26]</xref><xref ref-type="bibr" rid="article-24184.r27">[27]</xref><xref ref-type="bibr" rid="article-24184.r28">[28]</xref>&#x000a0;<xref ref-type="bibr" rid="article-24184.r29">[29]</xref>&#x000a0;Valproate,&#x000a0;lamotrigine,&#x000a0;and&#x000a0;topiramate&#x000a0;are&#x000a0;considered&#x000a0;first-line medications for LGS.<xref ref-type="bibr" rid="article-24184.r25">[25]</xref>&#x000a0;A summary of the medications is&#x000a0;as follows:&#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Felbamate:</italic>&#x000a0;Mainly treats atonic and tonic-clinic seizures. Although one of the first medications approved for LGS by the FDA (in 1993); it is also the last one to be used and only if all others fail (has multiple and severe side effects).<xref ref-type="bibr" rid="article-24184.r30">[30]</xref><xref ref-type="bibr" rid="article-24184.r31">[31]</xref><xref ref-type="bibr" rid="article-24184.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Lamotrigine:</italic>&#x000a0;Useful for tonic-clonic seizures and can potentially improve mood and behavior along with speech.<xref ref-type="bibr" rid="article-24184.r25">[25]</xref><xref ref-type="bibr" rid="article-24184.r26">[26]</xref>&#x000a0;The FDA approved it in 1998 to be used in combination with other medications for patients &#x0003e; 2 years of age.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Valproate:</italic>&#x000a0;Treats multiple seizure types. It is frequently started as the first medication and can be used as&#x000a0;monotherapy (since it treats different seizure types) or in combination with other medications.<xref ref-type="bibr" rid="article-24184.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Rufinamide:</italic>&#x000a0;Treats atonic and tonic-clonic seizures.<xref ref-type="bibr" rid="article-24184.r33">[33]</xref>&#x000a0;The FDA approved it in 2008 for treatment of LGS in children &#x0003e; 4 years of age or in adults. A distinction of rufinamide is that it does not make other seizure types worse.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Clobazam: </italic>It is a long-acting benzodiazepine and was approved by the FDA in 2011 as an adjunctive for the treatment of seizures in LGS patients &#x0003e; 2 years of age.<xref ref-type="bibr" rid="article-24184.r29">[29]</xref><xref ref-type="bibr" rid="article-24184.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Topiramate: </italic>Useful in treating tonic-clonic seizures. The FDA approved it as an add-on treatment for seizures in LGS in children &#x0003e;2 years of age.<xref ref-type="bibr" rid="article-24184.r25">[25]</xref><xref ref-type="bibr" rid="article-24184.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Cannabidiol&#x000a0;(CBD) oral solution:&#x000a0;</italic>It&#x000a0;has been found useful especially for drop attacks but also treats other seizures.<xref ref-type="bibr" rid="article-24184.r35">[35]</xref>&#x000a0;It is the latest medication approved by the FDA (in 2018) for children &#x0003e; 2 years of age with LGS.</p>
          </list-item>
          <list-item>
            <p>Medications like vigabatrin, zonisamide, ethosuximide, clonazepam, levetiracetam have also been used but not well studied&#x000a0;in regards to LGS.<xref ref-type="bibr" rid="article-24184.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Phenytoin, carbamazepine, oxcarbazepine, gabapentin, lacosamide, phenobarbital are not used as they can aggravate some&#x000a0;seizure types associated with LGS.<xref ref-type="bibr" rid="article-24184.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>There are reports that corticosteroid<xref ref-type="bibr" rid="article-24184.r37">[37]</xref> and intravenous immunoglobulin (IVIG)<xref ref-type="bibr" rid="article-24184.r38">[38]</xref> therapy may reduce seizure frequency but these reports are not backed by rigorous clinical studies.</p>
          </list-item>
        </list>
        <p><bold>Dietary management:&#x000a0;</bold>Seizures in LGS are often refractory to medical management. The next step is dietary modifications.&#x000a0;These modifications have been studied in children and adults and can decrease seizures and&#x000a0;perhaps reduce medication doses. Different diets that have been tested&#x000a0;include Ketogenic diet,<xref ref-type="bibr" rid="article-24184.r39">[39]</xref>&#x000a0;modified Atkins diet,<xref ref-type="bibr" rid="article-24184.r40">[40]</xref>&#x000a0;and low-glycemic-index diet, with some effect.<xref ref-type="bibr" rid="article-24184.r41">[41]</xref></p>
        <p><bold>Surgical management:</bold>&#x000a0;If medical management and dietary restrictions fail, the next step in the management of LGS is surgical management.<xref ref-type="bibr" rid="article-24184.r42">[42]</xref>&#x000a0;Specifically, surgical management is&#x000a0;considered&#x000a0;when the first two seizure medications fail. This could be in the form of vagus nerve stimulation (VNS)<xref ref-type="bibr" rid="article-24184.r41">[41]</xref> or brain surgery.</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Vagus Nerve Stimulation (VNS):&#x000a0;</italic>VNS&#x000a0;is combined with medical therapy and is most useful for the treatment of drop attacks and tonic-clonic seizures.<xref ref-type="bibr" rid="article-24184.r43">[43]</xref>&#x000a0;Interestingly, VNS results usually improve over time, unlike seizure medications. VNS can also be useful for mood and behavior improvement.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Brain surgery: </italic>Surgical options include resection, disconnection (corpus callosotomy), and hemispherectomy. In the past, LGS patients&#x000a0;were&#x000a0;considered&#x000a0;ineligible for surgery, as it&#x000a0;was thought to be a generalized epilepsy syndrome. However, patients with secondary LGS can have a resectable lesion (tubers, tumors, malformations) which is the source of seizure activity and can be considered for resection. In LGS, seizures tend to&#x000a0;affect both sides of the brain and disconnection by a corpus callosotomy is thought to stop the spread of the seizures from one side to the other. Corpus callosotomy is helpful with atonic, tonic, and tonic-clonic seizures.<xref ref-type="bibr" rid="article-24184.r44">[44]</xref>&#x000a0;A limited resection in the form of partial corpus callosotomy is often done&#x000a0;as well.<xref ref-type="bibr" rid="article-24184.r45">[45]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24184.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Since there is an evolution of symptoms with Lennox-Gastaut syndrome (LGS), it is difficult to arrive at a diagnosis right away and requires many years of follow-up.<xref ref-type="bibr" rid="article-24184.r46">[46]</xref>&#x000a0;Differential diagnoses include Dravet syndrome, myoclonic-atonic&#x000a0;epilepsy (Doose syndrome), atypical benign focal epilepsy of childhood, Pseudo-Lennox-syndrome, and West syndrome.<xref ref-type="bibr" rid="article-24184.r47">[47]</xref></p>
      </sec>
      <sec id="article-24184.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Overall, the outcome remains poor for patients with Lennox-Gastaut syndrome (LGS). The mortality rate is between 3% and 7% in 8 to 10 years of follow-up. Frequently, death can be from accidents. If there is a history of infantile spasms or West syndrome, the outcome is usually worse with seizure control as well as cognitive status<xref ref-type="bibr" rid="article-24184.r8">[8]</xref><xref ref-type="bibr" rid="article-24184.r7">[7]</xref>&#x000a0;while idiopathic LGS patients have less severe symptoms and resultant impairment. SUDEP or Sudden&#x000a0;Unexpected Death in Epilepsy may be&#x000a0;more common among LGS patients&#x000a0;as they&#x000a0;generally&#x000a0;have uncontrolled seizures<xref ref-type="bibr" rid="article-24184.r48">[48]</xref>.&#x000a0;</p>
      </sec>
      <sec id="article-24184.s10" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The frequent seizures, resultant intellectual impairment, and complex treatment regimen for a patient (child or adult) with Lennox-Gastaut syndrome (LGS) require substantial effort by the parents and family. The majority of the time, LGS patients will require 24/7 support in some form. A coordinated approach is needed from a team including a&#x000a0;pediatrician, neurologist, psychiatrist, neuropsychologist, and surgeon. Most patients and families will benefit from assessment and help from social and rehabilitation services (physical, occupational, and speech therapy). Efforts need to be made so that patients with&#x000a0;LGS&#x000a0;receive&#x000a0;early intervention whether it be regarding diagnosis, treatment, education, or support services. Families need to be given information about the LGS Foundation and the Epilepsy Foundation of America to optimize outcomes and improve quality of life.&#x000a0;</p>
      </sec>
      <sec id="article-24184.s11" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Every year, November 1 is observed as International Lennox-Gastaut Syndrome&#x000a0;(LGS) Awareness Day.</p>
      </sec>
      <sec id="article-24184.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Lennox-Gastaut syndrome (LGS) is a rare but severe form of childhood epilepsy characterized by a triad of multiple seizure types, characteristic EEG findings,&#x000a0;and intellectual impairment.&#x000a0;It is one of the epileptic encephalopathies. The frequent seizures, resultant intellectual impairment, and complex treatment regimen for a patient (child or adult) with Lennox-Gastaut syndrome (LGS) require substantial effort by the parents and family. The majority of the time, LGS patients will require 24/7 support in some form. A coordinated interprofessional team approach is needed to improve patient outcomes and quality of life. A team of clinicians including pediatricians, neurologists, psychiatrists, neuropsychologists, and often surgeons is needed to provide a comprehensive treatment plan while minimizing the adverse outcomes.</p>
        <p>A team of nurses consisting of pediatric specialty nurses and psychiatric specialty trained nurses is needed to assist the team to augment this treatment plan. The nurses are able to provide parents and patients with the necessary education in regards to the expected course and complications to allow early and prompt treatment of adverse events. The nurses can help individualize patient care by communicating these findings with the clinical providers.</p>
        <p>Given the side-effect profile and multitude of medications used to treat LGS the role of the pharmacists becomes vital in the care of LGS. The pharmacist can help directly in treatment planning by providing adequate treatment options and doses of each medication when used in combination with others. The pharmacist is essential in communicating with the providers potential adverse effects of the chosen regimen, as well as inter-drug interactions that may lower the efficacy of antiepileptic agents.&#x000a0;</p>
        <p>Most patients and families will benefit from assessment and help from social and rehabilitation services (physical, occupational, and speech therapy) to enhance the quality of life for both the patients and their caregivers.</p>
        <p>A collaborative interprofessional team approach is needed to ensure that patients with&#x000a0;LGS&#x000a0;receive&#x000a0;early intervention whether it be regarding diagnosis, treatment, education, or support services, to improve patient care and outcomes.&#x000a0;</p>
      </sec>
      <sec id="article-24184.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24184&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24184">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/child-health/lennox-gastaut-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24184">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24184/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24184">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-24184.s14">
        <fig id="article-24184.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Lennox-Gastaut Syndrome Chaitanya Amrutkar, MD and Rosario M Riel-Romero, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="LGS" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-24184.s15">
        <title>References</title>
        <ref id="article-24184.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gastaut</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tassinari</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Roger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soulayrol</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saint Jean</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Regis</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pinsard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dravet</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>[Epileptic encephalopathy in children with slow diffuse spike-wares (or petit mal variant) or Lennox syndrome].</article-title>
            <source>Recenti Prog Med</source>
            <year>1968</year>
            <month>Aug</month>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-46</page-range>
            <pub-id pub-id-type="pmid">4984443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LENNOX</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>DAVIS</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Clinical correlates of the fast and the slow spike-wave electroencephalogram.</article-title>
            <source>Pediatrics</source>
            <year>1950</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>626</fpage>
            <page-range>626-44</page-range>
            <pub-id pub-id-type="pmid">15417264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markand</surname>
                <given-names>ON</given-names>
              </name>
            </person-group>
            <article-title>Lennox-Gastaut syndrome (childhood epileptic encephalopathy).</article-title>
            <source>J Clin Neurophysiol</source>
            <year>2003</year>
            <season>Nov-Dec</season>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>426</fpage>
            <page-range>426-41</page-range>
            <pub-id pub-id-type="pmid">14734932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Archer</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Abbott</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Conceptualizing lennox-gastaut syndrome as a secondary network epilepsy.</article-title>
            <source>Front Neurol</source>
            <year>2014</year>
            <volume>5</volume>
            <fpage>225</fpage>
            <pub-id pub-id-type="pmid">25400619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camfield</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Definition and natural history of Lennox-Gastaut syndrome.</article-title>
            <source>Epilepsia</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>52 Suppl 5</volume>
            <fpage>3</fpage>
            <page-range>3-9</page-range>
            <pub-id pub-id-type="pmid">21790560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Al Baradie</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Epileptic encephalopathies: an overview.</article-title>
            <source>Epilepsy Res Treat</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>403592</fpage>
            <pub-id pub-id-type="pmid">23213494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trevathan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Yeargin-Allsopp</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children.</article-title>
            <source>Epilepsia</source>
            <year>1997</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>12</issue>
            <fpage>1283</fpage>
            <page-range>1283-8</page-range>
            <pub-id pub-id-type="pmid">9578523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohtahara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamatogi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohtsuka</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Prognosis of the Lennox syndrome-long-term clinical and electroencephalographic follow-up study, especially with special reference to relationship with the West syndrome.</article-title>
            <source>Folia Psychiatr Neurol Jpn</source>
            <year>1976</year>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>275</fpage>
            <page-range>275-87</page-range>
            <pub-id pub-id-type="pmid">992512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Widdess-Walsh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dlugos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fahlstrom</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shellhaas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>E</given-names>
              </name>
              <collab>EPGP Investigators</collab>
            </person-group>
            <article-title>Lennox-Gastaut syndrome of unknown cause: phenotypic characteristics of patients in the Epilepsy Phenome/Genome Project.</article-title>
            <source>Epilepsia</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>54</volume>
            <issue>11</issue>
            <fpage>1898</fpage>
            <page-range>1898-904</page-range>
            <pub-id pub-id-type="pmid">24116958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Selmer</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brandal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Undlien</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Brodtkorb</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>SCN1A mutation screening in adult patients with Lennox-Gastaut syndrome features.</article-title>
            <source>Epilepsy Behav</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>555</fpage>
            <page-range>555-7</page-range>
            <pub-id pub-id-type="pmid">19782004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Epi4K Consortium</collab>
              <collab>Epilepsy Phenome/Genome Project</collab>
              <name>
                <surname>Allen</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Berkovic</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Cossette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Delanty</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dlugos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Eichler</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Glauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Heinzen</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Hitomi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Howell</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kuzniecky</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Madou</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Marson</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Mefford</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Esmaeeli Nieh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Ottman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Petrovski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Poduri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruzzo</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Scheffer</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Sherr</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Yuskaitis</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Abou-Khalil</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alldredge</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Bautista</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Berkovic</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Boro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cascino</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Consalvo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Crumrine</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Devinsky</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dlugos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Fiol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fountain</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Glauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Glynn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haut</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Hayward</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Helmers</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kanner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kirsch</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Knowlton</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Kossoff</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Kuperman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kuzniecky</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Motika</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Novotny</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Ottman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paolicchi</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Parent</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Poduri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scheffer</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Shellhaas</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Sherr</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sirven</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lin Thio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Venkat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vining</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Von Allmen</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Weisenberg</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Widdess-Walsh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Winawer</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>De novo mutations in epileptic encephalopathies.</article-title>
            <source>Nature</source>
            <year>2013</year>
            <month>Sep</month>
            <day>12</day>
            <volume>501</volume>
            <issue>7466</issue>
            <fpage>217</fpage>
            <page-range>217-21</page-range>
            <pub-id pub-id-type="pmid">23934111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lund</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brodtkorb</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>&#x000d8;ye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>R&#x000f8;sby</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Selmer</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>CHD2 mutations in Lennox-Gastaut syndrome.</article-title>
            <source>Epilepsy Behav</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>33</volume>
            <fpage>18</fpage>
            <page-range>18-21</page-range>
            <pub-id pub-id-type="pmid">24614520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capelli</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Krepischi</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Gurgel-Giannetti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mendes</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Varela</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Koiffmann</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Deletion of the RMGA and CHD2 genes in a child with epilepsy and mental deficiency.</article-title>
            <source>Eur J Med Genet</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>55</volume>
            <issue>2</issue>
            <fpage>132</fpage>
            <page-range>132-4</page-range>
            <pub-id pub-id-type="pmid">22178256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bourgeois</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Douglass</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Sankar</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Lennox-Gastaut syndrome: a consensus approach to differential diagnosis.</article-title>
            <source>Epilepsia</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>55 Suppl 4</volume>
            <fpage>4</fpage>
            <page-range>4-9</page-range>
            <pub-id pub-id-type="pmid">25284032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heiskala</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Community-based study of Lennox-Gastaut syndrome.</article-title>
            <source>Epilepsia</source>
            <year>1997</year>
            <month>May</month>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>526</fpage>
            <page-range>526-31</page-range>
            <pub-id pub-id-type="pmid">9184597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asadi-Pooya</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Sharifzade</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lennox-Gastaut syndrome in south Iran: electro-clinical manifestations.</article-title>
            <source>Seizure</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>10</issue>
            <fpage>760</fpage>
            <page-range>760-3</page-range>
            <pub-id pub-id-type="pmid">22921514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crumrine</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Lennox-Gastaut syndrome.</article-title>
            <source>J Child Neurol</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>17 Suppl 1</volume>
            <fpage>S70</fpage>
            <page-range>S70-5</page-range>
            <pub-id pub-id-type="pmid">11918467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldsmith</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Zupanc</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Buchhalter</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Long-term seizure outcome in 74 patients with Lennox-Gastaut syndrome: effects of incorporating MRI head imaging in defining the cryptogenic subgroup.</article-title>
            <source>Epilepsia</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>395</fpage>
            <page-range>395-9</page-range>
            <pub-id pub-id-type="pmid">10756403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arzimanoglou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blume</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ernst</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Feucht</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Genton</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guerrini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pellock</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Perucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wheless</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology.</article-title>
            <source>Lancet Neurol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>82</fpage>
            <page-range>82-93</page-range>
            <pub-id pub-id-type="pmid">19081517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bare</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Glauser</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Strawsburg</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Need for electroencephalogram video confirmation of atypical absence seizures in children with Lennox-Gastaut syndrome.</article-title>
            <source>J Child Neurol</source>
            <year>1998</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>498</fpage>
            <page-range>498-500</page-range>
            <pub-id pub-id-type="pmid">9796756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oguni</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Osawa</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-term prognosis of Lennox-Gastaut syndrome.</article-title>
            <source>Epilepsia</source>
            <year>1996</year>
            <volume>37 Suppl 3</volume>
            <fpage>44</fpage>
            <page-range>44-7</page-range>
            <pub-id pub-id-type="pmid">8681912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glauser</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Following catastrophic epilepsy patients from childhood to adulthood.</article-title>
            <source>Epilepsia</source>
            <year>2004</year>
            <volume>45 Suppl 5</volume>
            <fpage>23</fpage>
            <page-range>23-6</page-range>
            <pub-id pub-id-type="pmid">15283708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asadi-Pooya</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Dlugos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Skidmore</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Atlas of Electroencephalography, 3rd Edition.</article-title>
            <source>Epileptic Disord</source>
            <year>2017</year>
            <month>Sep</month>
            <day>01</day>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>384</fpage>
            <pub-id pub-id-type="pmid">28872032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shyu</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Yiu</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>An atypical case of Lennox-Gastaut syndrome not associated with mental retardation: a nosological issue.</article-title>
            <source>Seizure</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>820</fpage>
            <page-range>820-3</page-range>
            <pub-id pub-id-type="pmid">21862354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michoulas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Medical management of Lennox-Gastaut syndrome.</article-title>
            <source>CNS Drugs</source>
            <year>2010</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>363</fpage>
            <page-range>363-74</page-range>
            <pub-id pub-id-type="pmid">20158289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Motte</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trevathan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Arvidsson</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Barrera</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Mullens</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Manasco</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group.</article-title>
            <source>N Engl J Med</source>
            <year>1997</year>
            <month>Dec</month>
            <day>18</day>
            <volume>337</volume>
            <issue>25</issue>
            <fpage>1807</fpage>
            <page-range>1807-12</page-range>
            <pub-id pub-id-type="pmid">9400037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sachdeo</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Glauser</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Ritter</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reife</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pledger</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group.</article-title>
            <source>Neurology</source>
            <year>1999</year>
            <month>Jun</month>
            <day>10</day>
            <volume>52</volume>
            <issue>9</issue>
            <fpage>1882</fpage>
            <page-range>1882-7</page-range>
            <pub-id pub-id-type="pmid">10371538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sachdeo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Krauss</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perdomo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arroyo</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome.</article-title>
            <source>Neurology</source>
            <year>2008</year>
            <month>May</month>
            <day>20</day>
            <volume>70</volume>
            <issue>21</issue>
            <fpage>1950</fpage>
            <page-range>1950-8</page-range>
            <pub-id pub-id-type="pmid">18401024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Conry</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Buchhalter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Isojarvi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Drummond</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clobazam is equally safe and efficacious for seizures associated with Lennox-Gastaut syndrome across different age groups: Post hoc analyses of short- and long-term clinical trial results.</article-title>
            <source>Epilepsy Behav</source>
            <year>2015</year>
            <month>May</month>
            <volume>46</volume>
            <fpage>221</fpage>
            <page-range>221-6</page-range>
            <pub-id pub-id-type="pmid">25940107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <collab>Felbamate Study Group in Lennox-Gastaut Syndrome</collab>
            <article-title>Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).</article-title>
            <source>N Engl J Med</source>
            <year>1993</year>
            <month>Jan</month>
            <day>07</day>
            <volume>328</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-33</page-range>
            <pub-id pub-id-type="pmid">8347179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devinsky</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Faught</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Wilder</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Kanner</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kamin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures.</article-title>
            <source>Epilepsy Res</source>
            <year>1995</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>241</fpage>
            <page-range>241-6</page-range>
            <pub-id pub-id-type="pmid">7796796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Neil</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Perdun</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>McGown</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Felbamate-associated fatal acute hepatic necrosis.</article-title>
            <source>Neurology</source>
            <year>1996</year>
            <month>May</month>
            <volume>46</volume>
            <issue>5</issue>
            <fpage>1457</fpage>
            <page-range>1457-9</page-range>
            <pub-id pub-id-type="pmid">8628501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaraba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Santamarina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mir&#x000f3;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Toledo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Molins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burcet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Becerra</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Raspall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pico</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Miravet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fossas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Falip</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Rufinamide in children and adults in routine clinical practice.</article-title>
            <source>Acta Neurol Scand</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>135</volume>
            <issue>1</issue>
            <fpage>122</fpage>
            <page-range>122-128</page-range>
            <pub-id pub-id-type="pmid">26923380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wheless</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Isojarvi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Drummond</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Benbadis</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Clobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience.</article-title>
            <source>Epilepsy Behav</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>41</volume>
            <fpage>47</fpage>
            <page-range>47-52</page-range>
            <pub-id pub-id-type="pmid">25282105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devinsky</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Marsh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Laux</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Flamini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wilfong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Filloux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tilton</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bruno</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bluvstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hedlund</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kamens</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maclean</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nangia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singhal</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cilio</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.</article-title>
            <source>Lancet Neurol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>270</fpage>
            <page-range>270-8</page-range>
            <pub-id pub-id-type="pmid">26724101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asadi-Pooya</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Emami</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ashjazadeh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nikseresht</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petramfar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yousefipour</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Borhani-Haghighi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Izadi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rahimi-Jaberi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Reasons for uncontrolled seizures in adults; the impact of pseudointractability.</article-title>
            <source>Seizure</source>
            <year>2013</year>
            <month>May</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>271</fpage>
            <page-range>271-4</page-range>
            <pub-id pub-id-type="pmid">23375939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pera</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Randazzo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Masnada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dontin</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>De Giorgis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Balottin</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Veggiotti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Intravenous methylprednisolone pulse therapy for children with epileptic encephalopathy.</article-title>
            <source>Funct Neurol</source>
            <year>2015</year>
            <season>Jul-Sep</season>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>173</fpage>
            <page-range>173-9</page-range>
            <pub-id pub-id-type="pmid">26910177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mikati</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kurdi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>El-Khoury</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Rahi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raad</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Intravenous immunoglobulin therapy in intractable childhood epilepsy: open-label study and review of the literature.</article-title>
            <source>Epilepsy Behav</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>90</fpage>
            <page-range>90-4</page-range>
            <pub-id pub-id-type="pmid">20004620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caraballo</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Fortini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fresler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Armeno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ariela</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cresta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mestre</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Escobal</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Ketogenic diet in patients with Lennox-Gastaut syndrome.</article-title>
            <source>Seizure</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>9</issue>
            <fpage>751</fpage>
            <page-range>751-5</page-range>
            <pub-id pub-id-type="pmid">25011392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gulati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sankhyan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Agarwala</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Use of the modified Atkins diet in Lennox Gastaut syndrome.</article-title>
            <source>J Child Neurol</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>576</fpage>
            <page-range>576-9</page-range>
            <pub-id pub-id-type="pmid">24659735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HD</given-names>
              </name>
            </person-group>
            <article-title>Low glycemic index treatment in patients with drug-resistant epilepsy.</article-title>
            <source>Brain Dev</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>39</volume>
            <issue>8</issue>
            <fpage>687</fpage>
            <page-range>687-692</page-range>
            <pub-id pub-id-type="pmid">28431772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Douglass</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Salpekar</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Surgical options for patients with Lennox-Gastaut syndrome.</article-title>
            <source>Epilepsia</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>55 Suppl 4</volume>
            <fpage>21</fpage>
            <page-range>21-8</page-range>
            <pub-id pub-id-type="pmid">25284034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lancman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Virk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mazumdar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Greenfield</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Vagus nerve stimulation vs. corpus callosotomy in the treatment of Lennox-Gastaut syndrome: a meta-analysis.</article-title>
            <source>Seizure</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-8</page-range>
            <pub-id pub-id-type="pmid">23068970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asadi-Pooya</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Malekmohamadi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kamgarpour</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rakei</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Taghipour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ashjazadeh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Inaloo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Razmkon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zare</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Corpus callosotomy is a valuable therapeutic option for patients with Lennox-Gastaut syndrome and medically refractory seizures.</article-title>
            <source>Epilepsy Behav</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>285</fpage>
            <page-range>285-8</page-range>
            <pub-id pub-id-type="pmid">24012506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asadi-Pooya</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Sharan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Corpus callosotomy.</article-title>
            <source>Epilepsy Behav</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>271</fpage>
            <page-range>271-8</page-range>
            <pub-id pub-id-type="pmid">18539083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Philip</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Evolution and management of Lennox-Gastaut syndrome through adolescence and into adulthood: are seizures always the primary issue?</article-title>
            <source>Epileptic Disord</source>
            <year>2011</year>
            <month>May</month>
            <volume>13 Suppl 1</volume>
            <fpage>S15</fpage>
            <page-range>S15-26</page-range>
            <pub-id pub-id-type="pmid">21669559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wirrell</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Whiting</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The epileptic encephalopathies of infancy and childhood.</article-title>
            <source>Can J Neurol Sci</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>409</fpage>
            <page-range>409-18</page-range>
            <pub-id pub-id-type="pmid">16408569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24184.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berg</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Nickels</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wirrell</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Geerts</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Callenbach</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Arts</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Rios</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Camfield</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Camfield</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Mortality risks in new-onset childhood epilepsy.</article-title>
            <source>Pediatrics</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>132</volume>
            <issue>1</issue>
            <fpage>124</fpage>
            <page-range>124-31</page-range>
            <pub-id pub-id-type="pmid">23753097</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
